Darren Foard

1.8k total citations
38 papers, 930 citations indexed

About

Darren Foard is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Darren Foard has authored 38 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 19 papers in Nephrology and 11 papers in Genetics. Recurrent topics in Darren Foard's work include Amyloidosis: Diagnosis, Treatment, Outcomes (38 papers), Parathyroid Disorders and Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Darren Foard is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (38 papers), Parathyroid Disorders and Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Darren Foard collaborates with scholars based in United Kingdom, United States and Italy. Darren Foard's co-authors include Ashutosh Wechalekar, Julian D. Gillmore, Philip N. Hawkins, Thirusha Lane, Lisa Rannigan, Helen J. Lachmann, Carol Whelan, Christopher P. Venner, Sajitha Sachchithanantham and Simon Gibbs and has published in prestigious journals such as Blood, Kidney International and European Respiratory Journal.

In The Last Decade

Darren Foard

35 papers receiving 916 citations

Peers

Darren Foard
Comparison fields: 5 of 32
  • Molecular Biology 904
  • Genetics 327
  • Epidemiology 219
  • Oncology 213
  • Nephrology 199
Replace Lisa Rannigan with:
Lisa Rannigan United Kingdom
Ray Comenzo United States
Kathleen T. Finn United States
Gabriele Sarais Italy
David Lavergne France
Mark Offer United Kingdom
James E. Hoffman United States
Steven R. Schuster United States
DV Faller United States
Xianghua Huang China
Lisa Rannigan United Kingdom View profile →
Citations per field, relative to Darren Foard
Darren Foard · 1×
Citations per year, relative to Darren Foard
Darren Foard · 1×

Countries citing papers authored by Darren Foard

Since Specialization
Citations

This map shows the geographic impact of Darren Foard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren Foard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren Foard more than expected).

Fields of papers citing papers by Darren Foard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren Foard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren Foard. The network helps show where Darren Foard may publish in the future.

Co-authorship network of co-authors of Darren Foard

This figure shows the co-authorship network connecting the top 25 collaborators of Darren Foard. A scholar is included among the top collaborators of Darren Foard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren Foard. Darren Foard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
2025 ·British Journal of Haematology ·Jahanzaib Khwaja, Sriram Ravichandran, Oliver C. Cohen, Darren Foard, (unknown), Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Carol Whelan, Shameem Mahmood, Ashutosh Wechalekar
1
2
Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver C. Cohen, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Amy A. Kirkwood, Ashutosh Wechalekar
0
3
Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, (unknown), Ashutosh Wechalekar
0
4
Refining prognostication in systemic AL amyloidosis: limited value of dFLC
2024 ·Amyloid ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver Cohen, Darren Foard, (unknown), Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, (unknown), Helen J. Lachmann, Shameem Mahmood, Ashutosh Wechalekar
3
5
Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients
2023 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver Cohen, Darren Foard, (unknown), Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh Wechalekar
5
6
Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis
2023 ·British Journal of Haematology ·Oliver Cohen, Regina Rendas‐Baum, Kristen McCausland, Darren Foard, Richa Manwani, Sriram Ravichandran, Helen J. Lachmann, Shameem Mahmood, Brendan Wisniowski, Philip N. Hawkins, Julian D. Gillmore, (unknown), Sabrina Rebello, Ashutosh Wechalekar
3
7
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
2021 ·Blood Cancer Journal ·Sriram Ravichandran, Oliver Cohen, Steven Law, Darren Foard, Marianna Fontana, Ana Martinez–Naharro, Carol Whelan, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Philip N. Hawkins, Ashutosh Wechalekar
20
8
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real‐world longitudinal data
2021 ·British Journal of Haematology ·Sriram Ravichandran, Oliver Cohen, Steven Law, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Marianna Fontana, Ana Martinez–Naharro, Carol Whelan, Julian D. Gillmore, Helen J. Lachmann, Philip N. Hawkins, Ashutosh Wechalekar
2
9
Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers
2019 ·British Journal of Haematology ·Tamer Rezk, Helen J. Lachmann, Marianna Fontana, (unknown), Sajitha Sachchithanantham, Shameem Mahmood, Aviva Petrie, Carol Whelan, Jennifer H. Pinney, Darren Foard, Thirusha Lane, Taryn Youngstein, Ashutosh Wechalekar, Philip N. Hawkins, Julian D. Gillmore
15
10
Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis
2018 ·British Journal of Haematology ·Tamer Rezk, Andrew Davenport, (unknown), Helen J. Lachmann, Marianna Fontana, Ana Martinez–Naharro, Sajitha Sachchithanantham, (unknown), Shameem Mahmood, Aviva Petrie, Carol Whelan, Jennifer H. Pinney, Darren Foard, Thirusha Lane, Taryn Youngstein, Ashutosh Wechalekar, Philip N. Hawkins, Julian D. Gillmore
4
11
Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study
2017 ·Blood ·Richa Manwani, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, Marianna Fontana, Carol Whelan, Candida Cristina Quarta, Thirusha Lane, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar
1
12
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor
2017 ·Kidney International ·Tamer Rezk, Helen J. Lachmann, Marianna Fontana, Sajitha Sachchithanantham, Shameem Mahmood, Aviva Petrie, Carol Whelan, Jennifer H. Pinney, Darren Foard, Thirusha Lane, Taryn Youngstein, Ashutosh Wechalekar, Paul Bass, Philip N. Hawkins, Julian D. Gillmore
19
13
Comparison of Free Light Chain Assays
2016 ·American Journal of Clinical Pathology ·Shameem Mahmood, (unknown), (unknown), Sajitha Sachchithanantham, Thirusha Lane, Darren Foard, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar
7
14
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis
2015 ·Haematologica ·Sajitha Sachchithanantham, Mark Offer, Christopher P. Venner, Shameem Mahmood, Darren Foard, Lisa Rannigan, (unknown), Julian D. Gillmore, Helen J. Lachmann, Philip N. Hawkins, Ashutosh Wechalekar
11
15
High prevalence of sleep disordered breathing (SDB) in patients with systemic AL amyloidosis
2014 ·European Respiratory Journal ·Shameem Mahmood, Leena George, Milind Sovani, Peter G. Smith, Philip N. Hawkins, Sajitha Sachchithanantham, Thirusha Lane, Lisa Rannigan, Darren Foard, Rabya Sayed, Ketna Patel, Marianna Fontana, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Ashutosh Wechalekar
1
16
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
2014 ·Leukemia ·Christopher P. Venner, Julian D. Gillmore, Sajitha Sachchithanantham, S. Mahmood, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon Gibbs, Jennifer H. Pinney, Carol Whelan, Helen J. Lachmann, Philip N. Hawkins, Ashutosh Wechalekar
64
17
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
2013 ·Blood ·Ashutosh Wechalekar, Stefan Schönland, Efstathios Kastritis, Julian D. Gillmore, Meletios Α. Dimopoulos, Thirusha Lane, Andrea Foli, Darren Foard, Paolo Milani, Lisa Rannigan, Ute Hegenbart, Philip N. Hawkins, Giampaolo Merlini, Giovanni Palladini
334
18
Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis
2013 ·Blood ·Sajitha Sachchithanantham, Shameem Mahmood, Rabya Sayed, Ketna Patel, Marianna Fontana, Thirusha Lane, Lisa Rannigan, Darren Foard, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar
2
19
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
2012 ·Blood ·Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon Gibbs, Jennifer H. Pinney, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar
197
20
A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.
2012 ·Blood ·Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Shameem Mahmood, Simon Gibbs, Jennifer H. Pinney, Sanjay M Banypersad, Jason Dungu, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar
2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Rannigan Breakdown of academic impact, for papers by Ray Comenzo Breakdown of academic impact, for papers by Kathleen T. Finn Breakdown of academic impact, for papers by Gabriele Sarais Breakdown of academic impact, for papers by David Lavergne Breakdown of academic impact, for papers by Mark Offer Breakdown of academic impact, for papers by James E. Hoffman Breakdown of academic impact, for papers by Steven R. Schuster Breakdown of academic impact, for papers by DV Faller Breakdown of academic impact, for papers by Xianghua Huang
Rankless by CCL
2026